Sony buys majority share in analysis firm STATSports

 Sony Corporation announced the acquisition of a majority share in STATSports Group, a global leader in athlete monitoring and performance analysis.

The deal brings STATSports' GPS-enabled wearable technologies used by over 800 elite teams, including England's national football team and the LA Dodgers, into Sony's expanding sports tech portfolio.

Sony aims to integrate STATSports with its existing ventures Hawk-Eye, KinaTrax, and Beyond Sports, enabling a full suite of optical and wearable tracking solutions for athletes, teams, and fans.

https://breakingthenews.net/Article/Sony-buys-majority-share-in-analysis-firm-STATSports/64945265

Macron's approval rating drops to 14%, poll shows

 French President Emmanuel Macron's approval rating fell by another 3 points to reach a historic low of 14%, according to a new poll published by Elabe on Wednesday.

The poll indicated that only 14% had faith in Macron to tackle the ongoing political crisis in the country after Prime Minister Sebastien Lecornu resigned on Monday, less than a day after unveiling his cabinet. Elabe stated that the latest drop in Macron's approval rating mirrored the failing popularity of his predecessor in office, Francois Hollande, whose approval also dropped to 14% in 2016. Additionally, it was noted that this was the lowest score measured since the pollster's inception. Moreover, 82% of those surveyed expressed distrust in the French president, with only 38% of his first-round voters in the presidential election saying they trust him.

The most popular politician currently is the leader of the National Rally (RN), Jordan Bardella, with 39%, followed by that party's former leader, Marine Le Pen, and former Prime Minister Edouard Philippe.

https://breakingthenews.net/Article/Macron's-approval-rating-drops-to-14-poll-shows/64947181

Shrinkflation? Coca-Cola to sell 7.5-oz mini cans in US stores

 The Coca-Cola Company announced on Wednesday that it will add its 7.5-oz mini cans of juice to its offer in convenience stores in the United States.

According to the beverage giant's statement, the new cans will hit the shelves on January 1, 2026, at a price of $1.29. They will be available for Coca‑Cola Original, Zero Sugar, Cherry, Sprite, and Fanta Orange, while limited-time flavors will rotate.

"People want more ways to enjoy Coca‑Cola on their terms – whether that's a smaller portion, a favorite classic or something new to try," Coca-Cola North America Operating Unit Commercial Leadership President Joel Bishop commented. "Convenience stores are where many of today’s quick decisions happen, and the cold vault plays a big role in those moments. By introducing mini cans into that space, we’re giving you more choice and making Coca‑Cola easier to enjoy and more accessible for the next generation."

https://breakingthenews.net/Article/Coca-Cola-to-sell-7.5-oz-mini-cans-in-US-stores/64947711

Israel said to sign Gaza deal 'in the next two days'

 Israel will sign the first phase of the deal with Hamas, paving the way for the immediate release of all hostages, Channel 14 reported on Wednesday, citing sources familiar with the matter.

Sources also said the disarmament of Hamas and the demilitarization of Gaza would be discussed "later," stressing that it will happen "for better or worse." If the first phase of the deal is signed and all hostages are released, Israel will release prisoners demanded by Hamas.

Earlier today, a Hamas official said the militant group exchanged the list of hostages and prisoners that would be released by both sides if the agreement is reached. Indirect negotiations between Israel and Hamas began on Monday, with Qatar, Egypt, and the United States acting as mediators.

https://breakingthenews.net/Article/Israel-said-to-sign-Gaza-deal-'in-the-next-two-days'/64947912

Saar slams French initiative amid Gaza talks

 Israeli Foreign Minister Gideon Saar criticized France's new diplomatic initiative on Wednesday, calling it "superfluous and harmful" as sensitive negotiations continue in Sharm el-Sheikh. Writing on X, Saar accused French President Emmanuel Macron of using Israel "to divert attention from his domestic problems."

He warned that the move could "compromise the crucial negotiations for the release of hostages, as has already happened in the past." Saar also condemned the inclusion of "governments openly hostile to Israel" in the so-called "New York Declaration" discussions, asserting that "no agreement in Gaza can be reached without Israel's consent." He also accused Paris of "double standards."

Senior diplomats from Europe, Arab nations, and other allied countries are set to meet in Paris on Thursday to discuss post-war governance in Gaza and support a permanent ceasefire under the US-backed Trump plan.

https://breakingthenews.net/Article/Saar-slams-French-initiative-amid-Gaza-talks/64947913

Xenetic first patient dosing in clinical trial involving its DNase I platform in combo with FOLFIRINOX

Xenetic first patient dosing in a clinical trial involving its DNase I platform in combination with FOLFIRINOX through a collaboration with PeriNess Ltd. This development highlights progress in the company's immuno-oncology efforts, particularly for pancreatic cancer treatments, building on recent expansions in partnerships like with Scripps for DNase-CAR T therapies. Social media buzz amplified the news, noting explosive pre-market gains up to 403% and strong retail interest in the micro-cap biotech's thin float, which often leads to high volatility. As a result, this positions the firm closer to Phase 1 trials, potentially attracting further investor attention amid a niche focus on rare disease R&D that can drive significant upside in the sector.

https://finviz.com/quote.ashx?t=XBIO&p=d

Astria Starts Phase 3 Orbit-Expanse Long-Term Trial of Navenibart in Hereditary angioedema

 -Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced the initiation of the Phase 3 ORBIT-EXPANSE long-term trial of navenibart in people living with hereditary angioedema (HAE).

"The initiation of ORBIT-EXPANSE marks exciting progress in the development of navenibart," said Christopher Morabito, M.D., Chief Medical Officer at Astria Therapeutics. "The entrance of eligible and interested participants into the ORBIT-EXPANSE long-term trial following the completion of the pivotal Phase 3 ALPHA-ORBIT trial highlights enthusiasm for navenibart, and we are deeply grateful to trial participants and site facilitators for their continued partnership."

The navenibart Phase 3 program consists of the ALPHA-ORBIT Phase 3 trial and ORBIT-EXPANSE long-term trial, which are designed to support registration globally. After completing ALPHA-ORBIT, eligible participants may continue into the ORBIT-EXPANSE trial, in which all participants will receive navenibart in either Q3M or Q6M regimens. The trial has two parts: in Part 1, participants will receive navenibart in a fixed dosing regimen for at least 6 months and, in Part 2, participants may move from one regimen to another based on their needs via a patient-centered flexible dosing period.

For more information on the ORBIT-EXPANSE long-term trial, please visit clinicaltrials.gov, NCT07204938. To learn more about the currently enrolling Phase 3 ALPHA-ORBIT trial, please visit AlphaOrbit.longboat.com, AstriaTrials.com, or clinicaltrials.gov, NCT06842823.

https://finance.yahoo.com/news/astria-therapeutics-initiates-phase-3-120000185.html